Lifastuzumab vedotin
Lifastuzumab vedotin (INN;[1] development code DNIB0600A) is a monoclonal antibody designed for the treatment of cancer.[2]
Monoclonal antibody | |
---|---|
Type | ? |
Source | Humanized (from mouse) |
Target | phosphate-sodium cotransporter |
Clinical data | |
Other names | DNIB0600A |
ATC code |
|
Identifiers | |
CAS Number | |
ChemSpider |
|
UNII | |
KEGG | |
Chemical and physical data | |
Formula | C6504H10028N1744O2018S46 |
Molar mass | 146416.72 g·mol−1 |
References
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.